Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting

Biomed Res Int. 2013:2013:730721. doi: 10.1155/2013/730721. Epub 2013 Sep 16.

Abstract

Introduction: Migration of the smooth muscle cells (SMCs) to the tunica media in the saphenous vein (SV) transplants is facilitated by matrix metalloproteinases (MMPs). The aim of this study was to identify any associations between expression of MMP-2 or endogenous tissue inhibitors (TIMP-2 and TIMP-3) in the SV segments and late failure of the SV grafts.

Methods: Two hundred consecutive patients with a mean age of 63.1 ± 8.9 years who underwent primary isolated venous CABG were examined. Patients were retrospectively split into two subgroups, with the SV graft disease (SVGD (+); n = 47) or without it (SVGD (-); n = 153). In the SV segments, immunohistochemical analysis of the expression of the MMP-2, TIMP-2, and -3 was performed.

Results: In the SVGD (+) patients, tissue expression of MMP-2 was stronger, whereas that of both TIMPs was weaker than in the SVGD (-) patients. In majority of the SV segments obtained from the SVGD (-) individuals, a balance in MMP and TIMP expressions was found, whereas an upregulation of MMP-2 expression was usually noted in the SVGD (+) subjects.

Conclusion: The strong expression of MMP-2 accompanied by reduced immunostaining of both TIMPs is associated with the development of the SV graft disease and unfavorable CABG outcomes.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Coronary Artery Bypass / adverse effects
  • Coronary Artery Bypass / methods*
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / biosynthesis*
  • Matrix Metalloproteinase 2 / metabolism
  • Middle Aged
  • Myocytes, Smooth Muscle / metabolism
  • Saphenous Vein / metabolism
  • Saphenous Vein / pathology
  • Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
  • Tissue Inhibitor of Metalloproteinase-3 / biosynthesis
  • Treatment Outcome
  • Tunica Media / metabolism*
  • Tunica Media / pathology

Substances

  • Tissue Inhibitor of Metalloproteinase-3
  • Tissue Inhibitor of Metalloproteinase-2
  • Matrix Metalloproteinase 2